Board Certified Pharmacogenomics Pharmacist (BCPGxP)

The Board Certified Pharmacogenomics Pharmacist (BCPGxP) credential is awarded to pharmacists who demonstrate advanced competence in applying genetic and genomic information to optimize medication therapy. This certification reflects a pharmacist’s ability to interpret pharmacogenomic test results, translate genotypes into clinically meaningful phenotypes, and apply evidence-based pharmacogenomic recommendations to patient-specific therapeutic decisions. Board Certified Pharmacogenomics Pharmacists play a key role in improving medication safety, reducing preventable adverse drug reactions, individualizing drug selection and dosing, supporting interprofessional clinical decision-making, and integrating pharmacogenomics into healthcare systems, ambulatory care, community pharmacy, oncology, psychiatry, cardiology, pain management, and precision medicine practice settings.

BCPGxP Exam Outline
Domain 1: Core Genomic and Genetic Foundations (20%)

  • Apply essential concepts of clinical genetics and genetic nomenclature.

  • Assess the role of major pharmacokinetic pharmacogenes.

  • Analyze the function of key pharmacodynamic pharmacogenes.

  • Explain the genetic basis of unpredictable or idiosyncratic drug reactions.

  • Apply principles of population genomics and ancestry-related variation.

  • Distinguish pharmacogenomics from other omics-based technologies.

Domain 2: Pharmacogenomic Testing and Result Interpretation (25%)

  • Determine the most appropriate pharmacogenomic test for a given clinical situation.

  • Compare PGx testing methods, platforms, and laboratory quality standards.

  • Convert genotype findings into clinically meaningful phenotypes.

  • Critically interpret pharmacogenomic laboratory reports.

  • Apply accepted standards for genetic variant classification.

  • Evaluate the clinical validity and practical utility of PGx testing.

Domain 3: Clinical Use and Therapeutic Decision-Making (30%)

  • Apply pharmacogenomic recommendations to cardiovascular therapies.

  • Use PGx guidance to optimize psychiatric medication therapy.

  • Apply pharmacogenomic principles to pain management medications.

  • Integrate PGx recommendations into oncology treatment decisions.

  • Manage complex drug–drug–gene interactions in patients with polypharmacy.

  • Adapt PGx recommendations for special patient populations.

Domain 4: Practice Implementation and Patient Education (15%)

  • Develop a structured clinical pharmacogenomics service or program.

  • Counsel patients effectively about their PGx results and medication implications.

  • Educate healthcare professionals on pharmacogenomics and its clinical value.

  • Build interprofessional training programs for PGx implementation.

  • Deliver pharmacogenomic counseling through telehealth platforms.

  • Provide culturally appropriate and health-literate PGx education.

Domain 5: Ethics, Regulation, and Health System Integration (10%)

  • Address ethical issues related to pharmacogenomic testing and result management.

  • Develop strategies to improve equity and access to PGx services.

  • Evaluate regulatory requirements governing PGx testing and related drug labeling.

  • Implement pharmacogenomics strategies across healthcare systems.

  • Assess economic, reimbursement, and business models for PGx services.

  • Collaborate with interprofessional teams to integrate PGx into patient care.

Recommended Resources

The following resources are provided as examples of study materials that may support preparation for the Board Certified Pharmacogenomics Pharmacist (BCPGxP) examination. This list is illustrative and not exhaustive.

Core References

  • Pharmacogenomics: An Introduction and Clinical Perspective

    A foundational reference for understanding genetic variation, pharmacogenomic testing, genotype-to-phenotype interpretation, and the clinical application of pharmacogenomics across therapeutic areas.

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines

    Essential evidence-based guidelines for applying pharmacogenomic test results to medication selection, dosing, and therapeutic decision-making.

  • PharmGKB

    A key pharmacogenomics knowledge resource supporting interpretation of gene–drug associations, clinical annotations, drug labels, and guideline-based recommendations.

Supplemental Resources

  • U.S. Food and Drug Administration (FDA)

    Selected drug labeling information, pharmacogenomic biomarker tables, and regulatory resources related to gene–drug interactions and medication safety.

  • Dutch Pharmacogenetics Working Group (DPWG)

    Selected pharmacogenomic recommendations and gene–drug guidance used internationally to support clinical decision-making.

  • Association for Molecular Pathology (AMP)

    Selected standards and recommendations related to pharmacogenomic allele selection, genetic testing terminology, and laboratory reporting.

  • American College of Medical Genetics and Genomics (ACMG)

    Selected resources related to genetic variant interpretation, ethical considerations, and responsible clinical use of genetic information.

  • Pharmacogenomic Testing and Evidence Retrieval Tools

    • PharmGKB

    • CPIC

    • ClinVar

    • PubMed / MEDLINE

    • FDA Drug Labels

© All rights reserved

Apply Now